top of page

Hello, I'm Andrographis

My Benefits

Supports Immunity

Andrographis may have a significant immune support, specifically for fighting infections and managing cancer. Studies show that andrographis has targeted anti-cancer activity on various human cancers, stimulates lymphocyte proliferation, and produces interleukin-2 (1). Other studies show that andrographis may cause cancer cell-cycle arrest at G0/G1 by inducing inhibitory proteins to slow the development of cancer (2).
Andrographis paniculata, AP3, has also been deemed a potentially cost-effective treatment to treat covid-19 infections in developing countries (3). 

Reduces Inflammation

Andrographolides are compounds specific to andrographis with strong anti-inflammatory effects. Studies show that andrographolides reduce inflammatory by enhancing immune function and stimulating T cells, natural killer cells, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (4). 

Other studies indicate that andrographis has strong anti-inflammatory effects which are achieved by interfering with COX and inflammatory cytokines, as well as modifying the expression genes that are involved in the inflammatory cascade (56). 

These effects are particularly useful for defending the body against viruses and bacteria (7). Andrographis may also have a strong potential to improve liver inflammation and HIV (89). 

Alters Gut Bacteria

Andrographis may offer support for a range of inflammatory digestive disorders. Studies show that andrographis is effective in relieving symptoms of ulcerative colitis (13). Others show that it may improve stress-related bowel conditions like diarrhea (14). 


Supports Respiratory Health

Clinical trials indicate that andrographis can offer prophylaxis and symptomatic relief for respiratory infections like the common cold, sinusitis, and others (11). Other studies concur that andrographis is effective for treating upper respiratory tract infections, and particularly helpful for improving symptoms related to the throat (12).

Relieves Allergy Symptoms

Studies show andrographis helps to manage allergies and chronic sinus infections by enhancing immune function and reducing inflammation in the sinuses and upper respiratory tract (10). 

Improves Mood

Studies show that andrographolides have a positive and protective effect on the central nervous system. Results indicate that andrographis moderates serum cortisol levels and may help manage stress, mood imbalances, and other cognitive issues (15). 


Improves Sleep

Studies show that andrographolide acts as an adaptogen, and can help to reduce stress-triggered physiological responses (16). This is closely related to improving sleep disruption and insomnia.




  1. R Ajaya Kumar et al. Anticancer and immunostimulatory compounds from Andrographis paniculata, Journal of Ethnopharmacology, Volume 92, Issues 2–3, 2004, Pages 291-295, ISSN 0378-8741,

  2. Rajagopal, S. et al. (2003), Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. Journal of Experimental Therapeutics and Oncology, 3: 147-158.

  3. Natarajan Arul Murugan et al (2020) Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials, Journal of Biomolecular Structure and Dynamics, DOI: 10.1080/07391102.2020.1777901

  4. Gupta, S. et al. Broad-spectrum antiviral properties of andrographolide. Arch Virol 162, 611–623 (2017). 

  5. Warisara Parichatikanond et al, Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (burm.f.) Nees and their effects on gene expression, International Immunopharmacology, Volume 10, Issue 11, 2010, Pages 1361-1373, ISSN 1567-5769,

  6. Nie, X. et al. Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway. Sci Rep 7, 4738 (2017). 

  7. Banerjee, M. et al. Andrographolide: antibacterial activity against common bacteria of human health concern and possible mechanism of action. Folia Microbiol 62, 237–244 (2017).

  8. Chua, L. S. (2014), Review on Liver Inflammation and Antiinflammatory Activity of Andrographis paniculata for Hepatoprotection, Phytother. Res., 28, pages 1589– 1598. doi: 10.1002/ptr.5193

  9. Calabrese, C. et al. (2000), A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother. Res., 14: 333-338.<333::AID-PTR584>3.0.CO;2-D

  10. Gabrielian ES et al. A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis. Phytomedicine. 2002 Oct;9(7):589-97. doi: 10.1078/094471102321616391. PMID: 12487322.

  11. Panossian A., Wikman G. (2013) Efficacy of Andrographis paniculata in Upper Respiratory Tract Infectious Diseases and the Mechanism of Action. In: Wagner H., Ulrich-Merzenich G. (eds) Evidence and Rational Based Research on Chinese Drugs. Springer, Vienna.

  12. J. Melchior et al, Double-blind, placebo-controlled pilot and Phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection, Phytomedicine, Volume 7, Issue 5, 2000, Pages 341-350, ISSN 0944-7113,

  13. Zhu, Qin et al. “Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.” American journal of translational research vol. 10,2 465-473. 15 Feb. 2018

  14. Nie, X., Chen, SR., Wang, K. et al. Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway. Sci Rep 7, 4738 (2017).

  15. Jiashu Lu et al, A review for the neuroprotective effects of andrographolide in the central nervous system, Biomedicine & Pharmacotherapy, Volume 117, 2019, 109078, ISSN 0753-3322,

  16. Thakur, Ajit Kumar et al. “Adaptogenic potential of andrographolide: An active principle of the king of bitters (Andrographis paniculata).” Journal of traditional and complementary medicine vol. 5,1 42-50. 19 Dec. 2014, doi:10.1016/j.jtcme.2014.10.002

bottom of page